Challenges and Insights in Absolute Quantification of Recombinant Therapeutic Antibodies by Mass Spectrometry: An Introductory Review
Antibodies · 07.01.2025 · 14 (1) · 3
DOI: 10.3390/antib14010003 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Antibodies, online erschienen am 07.01.2025. Verfasst von Sarah Döring und 4 weiteren Autor:innen. Beteiligte Einrichtung: Federal Institute of Material Testing and Research (BAM), 12489 Berlin, Germany. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 158 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
This review describes mass spectrometry (MS)-based approaches for the absolute quantification of therapeutic monoclonal antibodies (mAbs), focusing on technical challenges in sample treatment and calibration. Therapeutic mAbs are crucial for treating cancer and inflammatory, infectious, and autoimmune diseases. We trace their development from hybridoma technology and the first murine mAbs in 1975 to today’s chimeric and fully human mAbs. With increasing commercial relevance, the absolute quantification of mAbs, traceable to an international standard system of units (SI units), has attracted attention from science, industry, and national metrology institutes (NMIs). Quantification of proteotypic peptides after enzymatic digestion using high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) has emerged as the most viable strategy, though methods targeting intact mAbs are still being explored. We review peptide-based quantification, focusing on critical experimental steps like denaturation, reduction, alkylation, choice of digestion enzyme, and selection of signature peptides. Challenges in amino acid analysis (AAA) for quantifying pure mAbs and peptide calibrators, along with software tools for targeted MS data analysis, are also discussed. Short explanations within each chapter provide newcomers with an overview of the field’s challenges. We conclude that, despite recent progress, further efforts are needed to overcome the many technical hurdles along the quantification workflow and discuss the prospects of developing standardized protocols and certified reference materials (CRMs) for this goal. We also suggest future applications of newer technologies for absolute mAb quantification.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Federal Institute of Material Testing and Research (BAM), 12489 Berlin, Germany.
- Leibniz-Institut für Analytische Wissenschaften-ISAS-e.V., 44139 Dortmund, Germany.
ORCID-Profile: Sarah Döring, Michael G Weller, Yvonne Reinders, Zoltán Konthur, Carsten Jaeger
Zitieren
APA
Döring, S., Weller, M. G., Reinders, Y., Konthur, Z., & Jaeger, C. (2025). Challenges and Insights in Absolute Quantification of Recombinant Therapeutic Antibodies by Mass Spectrometry: An Introductory Review. Antibodies, 14(1), 3. https://doi.org/10.3390/antib14010003
Vancouver
Döring S, Weller MG, Reinders Y, Konthur Z, Jaeger C. Challenges and Insights in Absolute Quantification of Recombinant Therapeutic Antibodies by Mass Spectrometry: An Introductory Review. Antibodies. 2025;14(1):3. doi:10.3390/antib14010003
BibTeX
@article{Dring2025,
author = {Döring, Sarah and Weller, Michael G and Reinders, Yvonne and Konthur, Zoltán and Jaeger, Carsten},
title = {Challenges and Insights in Absolute Quantification of Recombinant Therapeutic Antibodies by Mass Spectrometry: An Introductory Review},
journal = {Antibodies},
year = {2025},
volume = {14},
number = {1},
pages = {3},
doi = {10.3390/antib14010003}
}
EUVIMED